ASCO Breast Cancer

Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer
June 11, 2018

The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.

Four-Gene Signature Identified Triple-Negative Breast Cancer Subgroups
June 12, 2017

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
June 12, 2017

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.